mirtazapine has been researched along with Anankastic Personality in 10 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our aim is to assess the efficacy of mirtazapine augmentation for patients with obsessive-compulsive disorder (OCD) who did not respond to sertraline monotherapy." | 9.69 | Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial. ( Baniasadipour, H; Mowla, A, 2023) |
| "A 44-year-old woman with a history of major depression and obsessive-compulsive disorder was prescribed mirtazapine." | 7.72 | Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. ( Chen, JL; Karwa, M; Spinowitz, N, 2003) |
| " Our aim is to assess the efficacy of mirtazapine augmentation for patients with obsessive-compulsive disorder (OCD) who did not respond to sertraline monotherapy." | 5.69 | Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial. ( Baniasadipour, H; Mowla, A, 2023) |
| "A 44-year-old woman with a history of major depression and obsessive-compulsive disorder was prescribed mirtazapine." | 3.72 | Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. ( Chen, JL; Karwa, M; Spinowitz, N, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mowla, A | 1 |
| Baniasadipour, H | 1 |
| Lim, LJH | 1 |
| Fong, LM | 1 |
| Hariram, J | 1 |
| Lee, YW | 1 |
| Tor, PC | 1 |
| Jaffe, RJ | 2 |
| Juneja, NS | 2 |
| Coffey, BJ | 1 |
| Waltereit, R | 1 |
| Eifler, S | 1 |
| Schirmbeck, F | 1 |
| Zink, M | 1 |
| Conrad, R | 1 |
| Wegener, I | 1 |
| Geiser, F | 1 |
| Imbierowicz, K | 1 |
| Liedtke, R | 1 |
| Egashira, N | 1 |
| Shirakawa, A | 1 |
| Abe, M | 1 |
| Niki, T | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Chen, JL | 1 |
| Spinowitz, N | 1 |
| Karwa, M | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Koran, LM | 2 |
| Gamel, NN | 1 |
| Choung, HW | 1 |
| Smith, EH | 1 |
| Aboujaoude, EN | 1 |
| Quirk, T | 1 |
| Lorberbaum, JP | 1 |
| Elliott, M | 1 |
4 trials available for mirtazapine and Anankastic Personality
| Article | Year |
|---|---|
Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial.
Topics: Humans; Mirtazapine; Obsessive-Compulsive Disorder; Sertraline | 2023 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Topics: Adult; Antidepressive Agents, Tricyclic; Diagnostic and Statistical Manual of Mental Disorders; Doub | 2005 |
Mirtazapine treatment of obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Dose-Response Relationship, Drug; Female; Humans; Male; Mia | 2001 |
6 other studies available for mirtazapine and Anankastic Personality
| Article | Year |
|---|---|
COVID-19, a pandemic that affects more than just physical health: Two case reports.
Topics: Adjustment Disorders; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; COVID-19; Fear; Female; Hu | 2020 |
Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety | 2018 |
Visual and auditory hallucinations associated with citalopram treatment.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive D | 2013 |
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.
Topics: Adult; Anorexia Nervosa; Benzodiazepines; Calcinosis; Combined Modality Therapy; Dominance, Cerebral | 2008 |
N-acetyl-L-cysteine inhibits marble-burying behavior in mice.
Topics: Acetylcysteine; alpha-Tocopherol; Animals; Antipsychotic Agents; Anxiety Disorders; Behavior, Animal | 2012 |
Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report.
Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Diabetic Ketoacidosis; | 2003 |